All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2021-02-11T12:35:00.000Z

ASH 2020 | Practice-changing abstracts in graft-versus-host disease

By Arnon Nagler, Robert Zeiser
Feb 11, 2021
Share:

Bookmark this article

Did you miss ASH 2020? The GvHD Hub attended the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a downloadable resource on the practice-changing abstracts in graft-versus-host disease (GvHD).

In this updated resource, you will find comments from the GvHD Hub Steering Committee members on novel treatments, ruxolitinib and belumosudil for steroid-refractory chronic GvHD.

ASH 2020 | Practice-changing abstracts in graft-versus-host disease

If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource below

Download Here

More about...
ASH 2020BelumosudilChronic graft-versus-host diseaseGraft-versus-host diseaseREACH3ROCKstarRuxolitinibSteroid-refractory GvHD

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
13 votes - 1 day left ...

Related articles

Add bookmark

Ruxolitinib shows improved overall response rate for patients with chronic GvHD

The Reach3 trial compared ruxolitinib with standard cGVHD therapies, and topline results show that the ruxolitinib treatment arm met the primary endpoint.

Jul 24, 2020
Add bookmark

Ruxolitinib shows improved overall response rate for patients with chronic GvHD

The Reach3 trial compared ruxolitinib with standard cGVHD therapies, and topline results show that the ruxolitinib...

Jul 24, 2020
Add bookmark

Editorial theme | Novel therapies for the treatment of GvHD

Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...

Feb 19, 2020
Add bookmark

Editorial theme | Novel therapies for the treatment of GvHD

Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in...

Feb 19, 2020

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox